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Comparative Effectiveness Associated With Buprenorphine and Naltrexone
in Opioid Use Disorder and Cooccurring Polysubstance Use
Kevin Y. Xu, MD, MPH; Carrie M. Mintz, MD; Ned Presnall, MSW; Laura J. Bierut, MD; Richard A. Grucza, PhD

Abstract

Key Points

IMPORTANCE Despite prevalent polysubstance use, treatment patterns and outcomes for
individuals with opioid use disorder (OUD) and cooccurring substance use disorders (SUD) are
understudied.

Question What is the prevalence and
comparative effectiveness associated
with buprenorphine and naltrexone in
individuals with opioid use disorder

OBJECTIVE To evaluate the distribution of buprenorphine and naltrexone initiation among
individuals with OUD with vs without cooccurring SUD and to assess the comparative effectiveness

(OUD) and cooccurring substance use
disorders (SUDs)?
Findings This comparative

associated with buprenorphine and naltrexone against drug-related poisonings.

effectiveness study evaluated 179 280

DESIGN, SETTING, AND PARTICIPANTS This observational comparative effectiveness study used

individuals with OUD using insurance

insurance claims from 2011 to 2016 from the US IBM MarketScan databases to study initiation of

claims. Individuals with OUD and

medications for OUD (MOUD) among treatment-seeking individuals aged 12 to 64 years with a

co-occurring SUDs were less likely to

primary diagnosis of OUD. Cooccurring SUD was defined as SUD diagnosed concurrent with or in the

receive buprenorphine and more likely

6 months prior to OUD treatment initiation. Treatment was codified as psychosocial treatment

to receive extended-release naltrexone

without MOUD or initiation or buprenorphine or naltrexone (including extended-release or oral).

than peers without polysubstance use;

Methadone recipients were excluded from analysis. Data were analyzed from February 3, 2021,

buprenorphine and extended-release

through February 26, 2022.

naltrexone were comparable in their
protective associations with drugrelated poisonings in both populations.

EXPOSURES MOUD.

Meaning These findings suggest that

MAIN OUTCOMES AND MEASURES Associations between cooccurring SUD diagnoses with
treatment type were assessed with multivariable regression. The association of drug-related
poisoning admissions with days covered with buprenorphine or naltrexone prescriptions vs days
without prescriptions was assessed among MOUD initiators. Odds ratios from within-person fixed
effects models were estimated as a function of MOUD and stratified by cooccurring SUDs.

individuals with cooccurring SUDs were
less likely to receive buprenorphine
despite buprenorphine’s association
with protecting against overdose in this
population.

RESULTS Among 179 280 individuals with OUD (mean [SD] age, 33.2 [11.0] years; 90 196 [50.5%]
men), 102 930 (57.4%) received psychosocial treatment without MOUD. Across 47 488 individuals
with cooccurring SUDs, 33 449 (70.4%) did not receive MOUD, whereas across 131 792 individuals
without cooccurring SUDs, 69 481 (52.7%) did not receive MOUD. Cooccurring SUD was associated

+ Supplemental content
Author affiliations and article information are
listed at the end of this article.

with decreased odds of initiating buprenorphine (risk ratio [RR], 0.55 [95% CI, 0.54-0.56]) but
increased odds of initiating naltrexone (extended release: RR, 1.12 [95% CI, 1.05-1.20]; oral: RR, 1.95
[95% CI, 1.86-2.03]). Among 12 485 individuals initiating MOUD who experienced at least 1 drugrelated poisoning during insurance enrollment, buprenorphine treatment days were associated with
decreased poisonings compared with days without MOUD for individuals with cooccurring SUD
(odds ratio [OR], 0.56 [95% CI, 0.48-0.65]) and individuals without cooccurring SUD (OR, 0.57 [95%
CI, 0.53-0.63]), with comparable associations observed for extended-release naltrexone. No
protective association was observed for oral naltrexone.
(continued)
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Abstract (continued)

CONCLUSIONS AND RELEVANCE These findings suggest that individuals with OUD and
polysubstance use were less likely to initiate buprenorphine and naltrexone than individuals without
polysubstance use. Among individuals initiating MOUD, polysubstance use was associated with
decreased buprenorphine and increased naltrexone initiation, despite buprenorphine’s protective
associations against drug-related poisoning.
JAMA Network Open. 2022;5(5):e2211363. doi:10.1001/jamanetworkopen.2022.11363

Introduction
The opioid overdose crisis in the US has evolved to become an epidemic of polysubstance use, with
opioids more commonly misused with alcohol, stimulants, and sedatives than alone.1,2 Despite a
higher likelihood of treatment discontinuation and overdose,3 polysubstance use in individuals with
opioid use disorder (OUD) is understudied and undertreated.3,4
To date, patterns of buprenorphine and naltrexone use among individuals with OUD and
cooccurring substance use disorders (SUD) has not been well-characterized in national samples in
the US. While medication for OUD (MOUD) receipt is posited to be lower in people with
polysubstance use, the comparative effectiveness of different MOUDs has not been thoroughly
investigated in such individuals.5,6 In the case of buprenorphine, individuals with cooccurring SUDs
have historically been deemed poor candidates for buprenorphine treatment, although recent
efforts have challenged such an approach to treatment.7 In the case of naltrexone, opioid antagonists
have garnered US Food and Drug Administration indications for both OUD and alcohol use disorder
(AUD); however, the effectiveness of naltrexone in treating OUD in individuals with cooccurring SUD
is not well studied, including potential protection against other drug-related adverse events. While
studies have suggested that opioid antagonists, such as naltrexone, lessen reinforcing effects of
multiple addictive substances, including from alcohol,8 opioids,9 stimulants,10,11 and sedatives,12 high
treatment discontinuation rates associated with naltrexone in studies of individuals with OUD6 have
raised questions about whether buprenorphine may hold similar promise in treating OUD in people
with cooccurring SUD. Research examining the comparative effectiveness of buprenorphine and
naltrexone in individuals with polysubstance use is thus needed.
Using a large national cohort of commercial insurance and Medicaid enrollees, we evaluated the
association between polysubstance use with buprenorphine and naltrexone use in individuals with
a primary diagnosis of OUD. Among individuals receiving buprenorphine or naltrexone, we examined
the association of buprenorphine and naltrexone use with nonfatal drug-related poisonings in
individuals with OUD and polysubstance use.

Methods
This comparative effectiveness study was deemed exempt from human participants review and
informed consent by the Washington University institutional review board because no identifiable
private data were used. This study is reported following the Strengthening the Reporting of
Observational Studies in Epidemiology (STROBE) reporting guideline and the Reporting of Studies
Conducted Using Observational Routinely Collected Health Data Statement for
Pharmacoepidemiology (RECORD-PE) reporting guideline.

Study Setting, Participants, and Observation Window
In this comparative effectiveness study, we used comprehensive insurance claims (ie, all paid
services, including outpatient, inpatient, and pharmacy) from the IBM MarketScan Commercial and
Multi-State Medicaid Databases from January 1, 2011, until December 31, 2016. Details on methods of
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data extraction have previously been described.13 Our analytic sample was derived from cohort of
206 909 individuals in the US aged 12 to 64 years with a primary OUD diagnosis and no previous
methadone treatment, defined by International Classification of Diseases, Ninth Revision (ICD-9) and
International Statistical Classification of Diseases and Related Health Problems, Tenth Revision
(ICD-10) codes, who had at least 1 period of continuous insurance enrollment and corresponding
treatment claim for 1 of the following: buprenorphine, extended-release (ER) naltrexone, oral
naltrexone, or psychosocial treatment without MOUD. Each period of continuous insurance coverage
ended when there was no claim for at least 45 days following the last dose of the most recent
prescription assumed to be used. We subsequently limited our sample to 179 280 individuals who
had a primary diagnosis of OUD and restricted the years of observation to 2011 to 2016, concomitant
with the introduction of ER naltrexone for OUD in 2011 (Figure 1). We conducted retrospective
analyses on this sample to evaluate the association between baseline cooccurring SUD, either
concurrent with or in the 6-month preceding OUD treatment initiation, and subsequent initiation of
buprenorphine or naltrexone during the individual’s first treatment episode. Individuals with history
of methadone treatment were not included, as methadone treatment programs are characterized by
close patient supervision and frequent drug testing14 that may confound observed associations
between medication treatment and outcomes. The diagnosis of OUD was based on ICD-9 and ICD-10
codes (eTable 1 in the Supplement).
To examine the comparative effectiveness of MOUD using within-person fixed effects
(case-crossover) models, we derived a subcohort of individuals from the analysis who experienced
any drug-related poisoning, defined as emergency department (ED) visit or inpatient hospitalization
and received any MOUD. This excluded 40 964 individuals who never received MOUD (naltrexone
or buprenorphine) during insurance coverage. We excluded 125 831 individuals who did not
experience a drug-related poisoning (outcome of interest) during coverage. We created an
observation window (period during which an individual was assessed for drug exposure) limited to 1
year before and after a person’s first (index) event to reduce heterogeneity in observation time,
culminating in 12 485 individuals encompassing 7 095 568 person-days.

Figure 1. Flowchart of Derivation of Analytic Sample
206 909 Individuals aged ≥12 y in insurance databases
(2006-2016) with prescription drug coverage,
primary diagnosis of OUD, no history of methadone
treatment and ≥1 insurance claim for OUD
treatment during enrollment period

31 767 Excluded with treatment claims
before 2011

179 280 Individuals in cohort to examine distribution of
buprenorphine and naltrexone among those
with and without cooccurring SUD
166 795 Excluded
40 964 Did not receive buprenorphine
or nalterxone during
insurance enrollment
125 831 Did not experience ≥1
drug-related poisoning after
initiation of OUD treatment
12 485 Individuals in subcohort to examine comparative
effectiveness of buprenorphine and naltrexone
among individuals with and without polySUDs, spanning 7 095 568 person-d 1 y before
and after index event
10 943 With ≥1 opioid-related poisoning after
initiation of OUD, spanning 5 468 367
person-d
3024 With ≥1 non–opioid-related poisoning after
initiation of OUD treatment, spanning
1 705 927 person-d
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Variables
For the analysis of polysubstance use and its association with MOUD initiation, the primary outcome
was OUD treatment type, operationalized as mutually exclusive categories of medication type (ie,
buprenorphine, oral naltrexone, or ER naltrexone) or psychosocial treatment without MOUD
(reference group). The exposure variable was presence of a cooccurring SUD in the 6-month
preceding treatment, spanning alcohol, stimulant (cocaine and/or amphetamines), and/or sedative
use disorder, as well as individuals without recent SUD diagnoses.
For the analysis of whether the protective associations of buprenorphine or naltrexone varied
based on presence of cooccurring SUD, the primary outcome variable was hospitalizations or ED
visits for any nonfatal drug-related poisoning (eTable 1 in the Supplement), derived from the US
Center for Disease Control and Prevention listing of ICD-9 and ICD-10 codes pertaining to poisoning
and pain.15 Secondary outcomes included opioid and nonopioid poisonings; drug-related poisonings
that did not include opioid-specific codes were classified as nonopioid related poisonings.15 The
exposure variables were medication use (buprenorphine or naltrexone [oral or ER]), coded as timevarying at the day level. Individuals were permitted to have multiple outcome events as long as they
fell within 1 year after the index event. To mitigate misclassification of acute events, we limited
place-of-service codes to hospital settings, EDs, ambulances, and inpatient psychiatry facilities, as
opposed to long-term care, office-based, and residential facilities. We coded case-days as “1,”
encompassing the index event and subsequent events, whereas control-days were coded as “0,”
encompassing remaining days in the observation window. Assuming prescription fills denoted
consumption of medication, we imputed medication treatment over time defined by presence or
absence of filled prescriptions; national drug codes and procedure codes for buprenorphine and
naltrexone have been detailed elsewhere.13 We coded medication days as “1” and nonmedication
days as “0” (reference group). To assess polysubstance use, we used ICD-9 and ICD-10 codes during
encounters to identify cooccurring SUDs at the time of OUD pharmacologic treatment initiation or
during the 6 months preceding treatment. We subsequently stratified between participants with
OUD and cooccurring SUD, as well as individuals without recent SUD diagnoses. Finally, we extracted
data on age, sex, self-reported race and ethnicity, cooccurring psychiatric diagnoses (ie, mood,
anxiety, psychotic, and personality disorders), Charlson comorbidity index, and insurance status for
purposes of sample description.

Statistical Analysis
We first conducted an analysis evaluating the association of buprenorphine or naltrexone initiation
during treatment in association with baseline cooccurring SUD diagnoses (assessed as 6 months prior
to, and inclusive of, OUD treatment initiation). Descriptive statistics evaluating the prevalence of
buprenorphine and naltrexone use were conducted, stratifying for cooccurring SUD diagnoses for all
individuals with a principal diagnosis of OUD, which is the first diagnosis recorded in an inpatient or
outpatient record (Table 1; eTable 3 in the Supplement) and for the subcohort of medication
recipients who had drug-related poisonings (eTable 2 and eTable 4 in the Supplement). The
association of cooccurring SUDs with MOUD initiation (buprenorphine, ER naltrexone, and oral
naltrexone vs psychosocial treatment without MOUD) was estimated using log-binomial regression
through generalized estimating equations with logarithmic link functions, controlling for age,
Medicaid status, and sex; we modeled the association of any cooccurring SUD and specific SUDs
(alcohol, stimulant, and sedative use disorders) separately.
Among the subcohort of individuals who received buprenorphine or naltrexone and had at least
1 drug-related poisoning, we conducted within-person longitudinal analyses to evaluate whether
buprenorphine or naltrexone use was associated with decreased risk of such events, both among
individuals with and without cooccurring SUDs. This analysis used a repeatable-event, casecrossover design previously described in detail.16 In brief, the case-crossover method characterizes
each person who experiences the outcome event over time by the presence or absence of treatment
with medications. Case periods included days when acute events occurred; control periods
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encompassed days when such events did not occur, with each individual used as their own control by
comparing buprenorphine or naltrexone prescriptions (exposure variable) at the time of event with
exposure during control periods (no event). As a within-person analysis, the case-crossover design
implicitly controls time-invariant confounding, although time-varying confounding is still an issue.
The repeatable-event approach partially mitigates this because time can be included as a covariate.17
The association between drug-related poisoning and medication (buprenorphine or naltrexone)
treatment days was estimated using conditional logistic regression.
To evaluate robustness of findings, we estimated models that included statins (negative control
not expected to influence drug-related poisoning risk) and benzodiazepines (which are common and
known to interact with buprenorphine in contributing to increased drug-related poisonings16) as
time-varying covariates. We conducted sensitivity analyses limiting analyses to individuals who had
an insurance claim for an OUD diagnosis in the 6 months preceding or including treatment initiation,
as well as analyses excluding individuals with cooccurring alcohol use disorder to elucidate
associations of naltrexone specifically, given its dual indications for alcohol use disorder and OUD.
Analyses were conducted using SAS statistical software version 9.4 (SAS Institute). P values
were 2-sided, and statistical significance was set at P = .05. Data were analyzed from February 3,
2021, through February 26, 2022.

Table 1. Characteristics of Treatment-Seeking Individuals With a Primary Diagnosis of OUD
No. (%)
Any cooccurring SUDa
Characteristic

All (N = 179 280)

Yes (n = 47 488)

No (n = 131 792 )

Type of OUD treatment during first treatment episode
Psychosocial treatment without medication

102 930 (57.4)

33 449 (70.4)

69 481 (52.7)

Buprenorphine

67 292 (37.5)

9651 (20.3)

57 641 (43.7)

ER naltrexone

3091 (1.7)

1156 (2.4)

1935 (1.5)

Oral naltrexone

5967 (3.3)

3232 (6.8)

2735 (2.1)

Sex
Men

90 196 (50.3)

24 968 (52.6)

65 228 (49.5)

Women

89 084 (49.7)

22 520 (47.4)

66 564 (50.5)

Private

84 136 (46.9)

20 961 (44.1)

63 175 (47.9)

Medicaid

95 144 (53.1)

26 527 (55.9)

68 617 (52.1)

Black

6362 (7.1)

2271 (9.1)

4091 (6.3)

Hispanic

1054 (1.2)

326 (1.3)

728 (1.1)

White

75 012 (83.6)

20 239 (81.4)

54 773 (84.4)

Insurance

Race and ethnicityb

Other

7318 (8.2)

2038 (8.2)

5280 (8.1)

33.2 (11.0)

33.4 (11.5)

33.1 (10.8)

Alcohol use disorder

30 767 (17.2)

30 767 (64.8)

NA

Stimulant use disorder

26 125 (14.6)

26 125 (55.0)

NA

Sedative use disorder

16 913 (9.4)

16 913 (35.6)

NA

Mood disorder

73 255 (40.9)

26 572 (56.0)

46 683 (35.4)

Psychotic disorder

5730 (3.2)

3149 (6.6)

2581 (2.0)

Personality disorder

5105 (2.9)

2740 (5.8)

2365 (1.8)

Abbreviations: NA, not applicable; OUD, opioid use
disorder; SUD, substance use disorder.

Anxiety disorder

62 036 (34.6)

21 532 (45.3)

40 504 (30.7)

a

SUDs were considered cooccurring in the 6 months
preceding or concurrent with OUD treatment
initiation.

b

Race and ethnicity data were available only for claims
from Medicaid databases. Other race or ethnicity
included people who did not disclose or who fell into
a category other than Black, Hispanic, or White.

Age, mean (SD), y
Nonopioid cooccurring substance use

Mental health condition

Charlson comorbidity index
0

160 267 (89.4)

40 136 (84.5)

120 131 (91.2)

1

13 923 (7.8)

5197 (10.9)

8726 (6.6)

2

3144 (1.8)

1232 (2.6)

1912 (1.5)

≥3

1946 (1.1)

923 (1.9)

1023 (0.8)
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Results
Sample and Treatment Characteristics
Analyses included 179 280 individuals seeking OUD treatment (mean [SD] age, 33.2 [11.0] years;
90 196 [50.3%] men), with 6362 Black individuals (7.1%), 1054 Hispanic individuals (1.2%), and
75 012 White individuals (83.6%), and 7318 individuals (8.2%) identified as other race or ethnicity,
including people who declined to answer or fell into categories other than Black, Hispanic, or White
(Table 1). There were 47 488 individuals (26.5%) with a cooccurring SUD during the baseline period.
Of all individuals, 67 292 (37.5%) received buprenorphine during the first treatment episode,
compared with 3091 individuals (1.7%) receiving ER naltrexone and 5967 individuals (3.3%) receiving
oral naltrexone. Additionally, 102 930 individuals (57.4%) received no buprenorphine or naltrexone
during the first treatment episode, of whom 40 964 individuals (39.8%) did not receive any
buprenorphine or naltrexone during insurance enrollment. With regards to cooccurring mental
health conditions overall, 62 036 individuals (34.6%) had a diagnosis for an anxiety order and 73 255
individuals (40.9%) had a diagnosis for a mood disorder; psychotic (5730 individuals [3.2%]) and
personality (5105 individuals [2.9%]) disorders were less common. Fewer than 5% of individuals had
a Charlson comorbidity index greater than 2. Table 1 depicts descriptive summaries of clinical and
demographic characteristics among all individuals with a primary diagnosis of OUD.
Of 47 488 individuals with a cooccurring SUD, 30 767 participants (64.8%) had alcohol use
disorder, 26 125 individuals (55.0%) had stimulant use disorder, and 16 913 individuals (35.6%) had
sedative use disorder at the start of the first treatment episode (Table 1; eTable 2 in the Supplement).
The subcohort used in the within-person (case-crossover) analysis of drug-related poisonings in
association with medication treatment periods is described in eTable 2 and eTable 4 in the
Supplement; of 12 485 individuals who experienced drug-related poisonings, 10 502 individuals
(84.1%) had more than 1 event.
A total of 33 449 individuals (70.4%) with cooccurring SUD during baseline received treatment
without MOUD during first treatment episode, compared with 69 481 individuals (52.7%) without
cooccurring SUD (Table 1). Whereas 9651 individuals (20.3%) with cooccurring SUD received
buprenorphine, 57 641 individuals (43.7%) without cooccurring SUD received buprenorphine.
Conversely, whereas among those with cooccurring SUD, 1156 individuals (2.4%) received ER
naltrexone and 3232 individuals (6.8%) received oral naltrexone, among those without cooccurring
SUD, only 1935 individuals (1.5%) received ER naltrexone and 2735 individuals (2.1%) received oral
naltrexone.

Association of Polysubstance Use With MOUD Initiation
Multivariable log-binomial analyses of the association between cooccurring SUD and medication
initiation during the first treatment episode while controlling for age, Medicaid status, and sex are
shown in Table 2. The presence of any cooccurring SUD was associated with decreased likelihood of
buprenorphine treatment at time of OUD treatment initiation (risk ratio [RR], 0.55 [95% CI,

Table 2. Adjusted Odds of OUD Medication Receipt in Association with Cooccurring Substance Use Disorders Among All Treatment-Seeking Individuals
With a Primary Diagnosis of Opioid Use Disorder
Buprenorphinea
Parameter

ER naltrexonea

Oral naltrexone a

OR (95% CI)

P value

OR (95% CI)

P value

OR (95% CI)

P value

0.55 (0.54-0.56)

<.001

1.12 (1.05-1.20)

<.001

1.95 (1.86-2.03)

<.001

Alcohol use disorder

0.60 (0.59-0.61)

<.001

1.22 (1.13-1.31)

<.001

2.11 (2.02-2.20)

<.001

Stimulant use disorder

0.66 (0.65-0.68)

<.001

0.93 (0.86-1.01)

.10

1.06 (1.00-1.11)

.05

Sedative use disorder

0.73 (0.72-0.75)

<.001

0.90 (0.82-0.99)

.002

0.95 (0.90-1.01)

.11

Model 1
Any cooccurring SUD
Model 2

Abbreviations: ER, extended release; OR, odds ratio; SUD, substance use disorder.
a

For all analyses, ORs were calculated as the odds of receiving the medication compared with the reference group of no cooccurring use disorder.
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0.54-0.56]), compared with increased likelihood of ER naltrexone (RR, 1.12 [95% CI, 1.05-1.20]) and
oral naltrexone (RR, 1.95 [95% CI, 1.86-2.03]) treatment initiation. In model 2 assessing individual
cooccurring SUDs, there was decreased likelihood of buprenorphine initiation with cooccurring
alcohol use disorder (RR, 0.60 [95% CI, 0.59-0.61]), stimulant use disorder (RR, 0.66 [95% CI,
0.65-0.68]), and sedative use disorder (RR, 0.73 [95% CI, 0.72-0.75]). While cooccurring alcohol use
disorder was associated with increased initiation of ER naltrexone (RR, 1.22, [95% CI, 1.13-1.31]) or
oral naltrexone (RR, 2.11 [95% CI, 2.02-2.20]), we did not observe an association between stimulant
or sedative use disorders and naltrexone initiation, apart from a decrease in ER naltrexone
prescriptions in individuals with cooccurring sedative use disorder (RR, 0.90 [95% CI, 0.82-0.99]).

Polysubstance Use and Comparative Effectiveness Associated With MOUD
As depicted in Figure 2A, buprenorphine treatment days were associated with lower odds of
hospitalization or ED visit for acute drug-related poisonings among individuals with cooccurring SUD
(odds ratio [OR], 0.56 [95% CI, 0.48-0.65]) and those without cooccurring SUD (OR, 0.57 [95% CI,
0.53-0.63]). Comparable protective associations were observed in association with ER naltrexone
treatment days for individuals with cooccurring SUD (OR, 0.44 [95% CI, 0.30-0.63]) but not for
individuals without cooccurring SUD. No protective association was observed for oral naltrexone.
In secondary analyses stratifying by event subtype, buprenorphine was associated with
decreased opioid-specific poisonings across individuals with cooccurring SUD (OR, 0.51 [95% CI,
0.43-0.61]) and without cooccurring SUD (OR, 0.49 [95% CI, 0.44-0.55]), with similar associations
observed for ER naltrexone (eFigure in the Supplement). While oral naltrexone was associated with
decreased opioid-specific admissions for individuals with cooccurring SUD (OR, 0.53 [95% CI,
0.36-0.77]), no association was observed among individuals without cooccurring SUD. Notably,
while buprenorphine exhibited protective associations with decreased nonopioid poisonings among
individuals with cooccurring SUD (OR, 0.64 [95% CI, 0.49-0.85]) and those without cooccurring
SUD (OR, 0.79 [95% CI, 0.67-0.94]), no protective associations were observed for ER or oral
naltrexone with nonopioid poisonings (eFigure in the Supplement).
In further secondary analyses, we evaluated the comparative effectiveness of MOUD with
individual cooccurring SUDs, observing comparable protective associations with buprenorphine
treatment days for individuals without cooccurring SUD (OR, 0.57 [95% CI, 0.53-0.63]) and those

Figure 2. Odds of Acute Drug-Related Poisonings Associated With OUD Treatment Days Compared With Nontreatment Days, Stratified
by Any Substance Use Disorder (SUD) Diagnosis During the 6 Months Preceding Treatment Initiation
A Any cooccurring SUD diagnosis

B
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Alcohol use disorder

Buprenorphine
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Odds ratios were calculated among 12 485 individuals encompassing 7 095 568 person-days. ER indicates extended release.
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with alcohol use disorder (OR, 0.57 [95% CI, 0.47-0.69]), stimulant use disorder (OR, 0.78
[0.63-0.96]), and sedative use disorder (OR, 0.79 [95% CI, 0.64-0.98]) (Figure 2). While no
association was observed between ER naltrexone and odds of drug-related poisoning for individuals
with cooccurring sedative use disorder, comparable results were otherwise observed in all other
comparisons (Figure 2). No protective association was observed for oral naltrexone.
These associations were sustained in sensitivity analyses controlling for benzodiazepines
(positive control,) and statins (negative control) (eFigure in the Supplement), with univariate
distributions of benzodiazepine and statin use (eTable 5 in the Supplement). The protective
associations of buprenorphine and naltrexone were also sustained in analyses that limited events to
those that occurred among individuals without a concurrent alcohol use disorder diagnosis (eFigure
in the Supplement) and individuals with an active OUD diagnosis in the electronic medical record at
the time of ED visit or hospitalization (eFigure in the Supplement).

Discussion
In this comparative effectiveness study assessing individuals with OUD, more than 50% of
individuals with OUD without cooccurring SUD and more 70% of individuals with cooccurring SUD
did not receive evidence-based MOUD at time of treatment initiation. This indicates significant
treatment gaps in a particularly high-risk population. While clinical studies have revealed similar
efficacy of buprenorphine and naltrexone in treatment of OUD in per protocol analyses,18 our
analysis found that the distribution of buprenorphine and naltrexone prescriptions in clinical practice
varied based on the presence of a cooccurring SUD, such that individuals with cooccurring SUDs may
be more likely to receive naltrexone and less likely to receive buprenorphine. Existing research shows
polysubstance use is associated with lower likelihood of buprenorphine receipt,3,13 and although the
American Society of Addiction Medicine has advised that cooccurring SUDs should not result in
suspension of OUD treatment,7 polysubstance use remains associated with stigma, opioid agonist
treatment underdosing,19 and exclusion from treatment.1,20 A 2020 analysis of US veterans reported
lower likelihood of buprenorphine receipt associated with cooccurring SUDs.3 A 2021 analysis of US
insurance claims found that opioid agonist therapy was underprescribed to individuals with OUD and
alcohol use disorder.13 The level of abstinence historically required for patients to remain in
buprenorphine treatment has been identified as a factor associated with low buprenorphine
initiation and retention in treatment,20 potentially explaining low utilization rates among individuals
with cooccurring SUDs.
In addition, we found consistent protective associations of both buprenorphine against drugrelated poisonings across multiple types of cooccurring SUDs, with comparable associations
observed for ER naltrexone. While naltrexone has been regarded as a promising treatment for
individuals with OUD and polysubstance use, the effectiveness of naltrexone in clinical practice is
limited by the requirement to complete detoxification prior to induction, elevated treatment
discontinuation,13 and elevated overdose rates while receiving medication compared with
buprenorphine.5,6 We found that oral naltrexone was not associated with significant protective
associations against drug-related poisoning across most analyses; this is consistent with previous
literature reporting high treatment discontinuation and overdose rates associated with oral
naltrexone among individuals with OUD.21

Limitations
This study has some limitations, including unmeasured confounding and measurement error, as
prescription coverage and fills data do not always reflect actual consumption, as well as lower rates
of naltrexone receipt compared with buprenorphine. Future research is needed to assess time using
and not using medication (ie, treatment discontinuation risk). Although we adjusted for both
calendar-time and restricted individuals to 2-year observation periods surrounding the index drugrelated poisoning to reduce heterogeneity in observation time, unmeasured time-varying
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confounding is possible, such as engagement with the health care system, although we found no
significant protective associations with statins (negative control). Bias resulting from control period
selection as a function of event time cannot be ruled out, although our design benefited from
bidirectional time sampling, with past results in this study cohort being robust to the choice of
control period window.16 Our results are also limited by lack of race and ethnicity data in commercial
insurance claims, limiting our ability to study the associations of structural racism in shaping
outcomes in individuals with cooccurring SUD. These findings also predate the surge of synthetic
opioid use in the late 2010s, further external validity.
Additionally, while recent studies22 have shown poor positive predictive values of ICD codes for
OUD, our analysis was conducted on treatment-seeking individuals with a primary diagnosis of OUD
who were likely to have a high severity of substance use and its concomitant impairment,23 rendering
it more likely that our sample was correctly capturing individuals with active OUD. We also conducted
sensitivity analyses that eliminated individuals with cooccurring alcohol use disorder and limited
observations to those with active OUD claims, illustrating robustness of our main effects. Our study
is also strengthened by use of repeatable-event case-crossover design, mitigating bias from timeinvariant confounding, as each participant acted as his or her own control.

Conclusions
The findings of this comparative effectiveness study provide insight into the high-risk and
understudied population of individuals with OUD and cooccurring SUDs during a time when the
opioid overdose epidemic is evolving into a polysubstance use crisis. We found that individuals with
OUD and polysubstance use had a lower distribution of buprenorphine initiation even though
buprenorphine demonstrated potentially more robust protective associations against acute drugrelated events compared with ER naltrexone. Targeted efforts are needed to expand access to MOUD
in individuals with polysubstance use.
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